Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.

Vaccine Injury Compensation Program Follow developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies; international vaccine issues; vaccine policy at the Pan American Health Organization; HR 3610 HR 5629 Childhood immunizations Dietary supplement issues Implementation issues concerning P.L. 108-173 - The Medicare Prescription Drug, Improvement and Modernization Act of 2003 Drug compounding Alzheimer's care Comparative effectiveness - S.3408 - Comparative Effectiveness Research Act of 2008 S. 1695 Biologics Price Competition and Innovation Act of 2007 H.R. 1812 - Menopausal Hormone Replacement Therapies and Alternative Treatments and Fairness Act Pediatric Studies and Trials Drug Safety/Clinical Trials H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007 S. 623/HR 1038 - Access to Life Saving Medicine Act, Follow-on Biologics S. 1505 - Affordable Biologics for Consumers Act H.R. 3610 - Food and Drug Import Safety Act of 2007 S.2029 - Vaccine Safety and Payment Health care issues Drug approvals Reimbursement rates S. 334 The Healthy Americans Act H.Con.Res. 342 (BHRT) FDA Pre-emption S.3613, H.R. 7114 - Independence at Home Act S.3409-Drug and Device Accountability Act of 2008 Follow-on biologics Drug importation and counterfeiting Drug advertising Comparative effectiveness Physician payment disclosure Hormone replacement therapies Chronic Illness International public health issues International vaccine issues

Client expense: $1,047,210 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of the Vice President of the United States, SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $20,000

H.R. 7120, To amend the Federal Food, Drug, and Cosmetic Act concerning the distribution and citation of scientific research in connection with foods and dietary supplements, and for other purposes. Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens: Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $20,000

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $20,000

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $20,000

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

H. Con. Res. 342 S. Con. Res. 88 General Health Care Reform FDA Reform

Client expense: $10,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues related to compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drig Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues related to compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drig Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues related to compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drig Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Vaccine Injury Compensation Program Follow developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies; international vaccine issues; vaccine policy at the Pan American Health Organization; HR 3610 HR 5629 Childhood immunizations Dietary supplement issues Implementation issues concerning P.L. 108-173 - The Medicare Prescription Drug, Improvement and Modernization Act of 2003 Drug compounding Alzheimer's care Comparative effectiveness - S.3408 - Comparative Effectiveness Research Act of 2008 S. 1695 Biologics Price Competition and Innovation Act of 2007 H.R. 1812 - Menopausal Hormone Replacement Therapies and Alternative Treatments and Fairness Act Pediatric Studies and Trials Drug Safety/Clinical Trials H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007 S. 623/HR 1038 - Access to Life Saving Medicine Act, Follow-on Biologics S. 1505 - Affordable Biologics for Consumers Act H.R. 3610 - Food and Drug Import Safety Act of 2007 S.2029 - Vaccine Safety and Payment Health care issues Drug approvals Reimbursement rates S. 334 The Healthy Americans Act H.Con.Res. 342 (BHRT) FDA Pre-emption S.3613, H.R. 7114 - Independence at Home Act S.3409-Drug and Device Accountability Act of 2008 Follow-on biologics Drug importation and counterfeiting Drug advertising Comparative effectiveness Physician payment disclosure Hormone replacement therapies

Client expense: $756,650 · Firm income: Not reported

H. Con. Res. 342 - FDA Resolution S. Con. Res. 88 - FDA Resolution FDA Reform - Reform of FDAMA (Food and Drug Act Statutes)

Client expense: Not reported · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1424 Paul Wellstone Mental Health and Addiction Equity Act H.R. 5501 Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act H.R. 5918 Small Business Health Options Program Act H.R. 6210 Small Business Health Options Program Act H.R. 6357 Protecting Records, Optimizing Treatment, and Easing Communication through Healthcare Technology Act H.R. 7016 Susan B. Anthony Prenatal Nondiscrimination Act H.R. 7067 Quality FIRST (From Incentives, Reporting, Standards, and Technology) Act S. 558 Mental Health Parity Act S. 1693 Wired for Health Care Quality Act S. 2731 Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act S. 2795 Small Business Health Options Program Act S. 3408 Comparative Effectiveness Research Act H. Con. Res. 342 Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. S. Con. Res. 88 Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. Docket No. DEA 218 Electronic Prescriptions for Controlled Substances, CFR Parts 1300, 1304, 1306, 1311 RIN 0991-AB48 Provider Conscience Regulations Request for language in the standards governing ICE detention practices that prohibits the use of shackles or restraints on pregnant women in ICE custody

Client expense: $25,000 · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $60,000

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)

Client expense: Not reported · Firm income: $60,000

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported

Issues Related to compounding pharmacies, in particular to FDA action to ban estriol or further restrict access to estriol or other drus used in the compounding process. Specifically working on H. Con. Res. 342 and S. Con Res. 88, as well as FDA Reauthorization and drug-specific bills (the DXM access bill: H.R. 970 and S. 1378.

Client expense: Not reported · Firm income: Not reported